The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The safety and efficacy of elotuzumab for the treatment of multiple myeloma
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the safety and efficacy of elotuzumab for the treatment of multiple myeloma, drawing focus on updated results from the SWOG-1211 trial (NCT01668719). Dr Richardson comments on the encouraging survival data observed with the addition of elotuzumab to bortezomib, lenalidomide and dexamethasone (RVd), and further emphasizes the tolerability of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
